Key Highlights

  • The closing order book reached £1,399m, up 8% year on year, a record for the group.
  • First-half Revenue rose 6.5% to £237.3m but underlying operating profit fell 7.5% to £24.5m.
  • Net Debt climbed to £144.5m from £89.0m, reflecting £44m of Capital spending on energetics expansion.
  • New capacity is expected to add around £100m of annual revenue and £30m of operating profit by 2028.

Chemring Group PLC (LSE:CHG) is heading into a Leadership change at the same time as it carries the largest order book in its history. On 30 July 2026 the FTSE 250 defence group announced that Group Chief Executive Michael Ord will retire on 1 January 2027, handing over to Babcock International veteran Tom Newman, who joins as Chief Executive Designate on 5 October 2026.

The handover comes at a delicate point. Interim results on 2 June 2026 showed a record £1.4bn order book and 6.5% revenue growth, but also a lower operating margin, a sharp rise in net debt as the group builds new explosives capacity, and continued disruption in the UK market. With the shares at 533p on 2 September 2026, valuing the group at about £1.45bn, the question is whether Chemring's multi-year capacity bet pays off under new management.

CEO succession and a $345m countermeasures win

The most significant recent development is the succession announcement of 30 July 2026. Michael Ord, who has led Chemring for eight years, will step down on 1 January 2027. His successor, Tom Newman, spent 17 years at Babcock International, most recently running its Land and UK Aviation sector, a Business with around £1bn of revenue. Chairman Tony Wood said Ord had been "an exceptional Chief Executive, leading Chemring through a period of significant transformation to build a stronger, more successful and growing business". Newman described the group as "well placed with a strong market position, exceptional people and an exciting future".

The change follows a burst of contract news. On 25 June 2026 Chemring's Philadelphia-based Subsidiary Alloy Surfaces Company secured a five-year IDIQ contract worth up to $300m from the US Department of War, with $35m guaranteed annually for the first three years, plus a separate $45m agreement, both for pyrophoric airborne decoys, with deliveries from early FY28. Alloy Surfaces had been classified as held for sale in the FY25 accounts; the awards return it to continuing operations.

On 1 July 2026 Chemring Sensors & Electronic Systems won a sole-source full-rate production award for the Joint Biological Tactical Detection System from the US Department of Defense, with a $48.8m IDIQ ceiling and an initial $36.3m production contract running to March 2028.

What Chemring does

Chemring is a London Stock Exchange-listed manufacturer of countermeasures, energetic materials and specialist sensor and information technology, employing around 2,700 people with Manufacturing in four countries and sales into more than 50 nations, according to its FY25 results.

Countermeasures & Energetics, the larger division, produces flares and decoys that protect military aircraft and ships from missiles, alongside military explosives, propellants and energetic devices used in munitions, missiles and space launch systems. Key sites include Tennessee, Scotland and Chemring Nobel in Norway.

Sensors & Information is centred on Roke, the UK technology business supplying electronic warfare, cyber and intelligence capabilities largely to UK government customers, together with US chemical and biological detection specialist Chemring Sensors & Electronic Systems. Roke bought Landguard Systems for £20m in August 2025.

Half-year results: revenue up 6.5%, margin down, net debt up

For the six months to 30 April 2026, revenue rose 6.5% to £237.3m from £222.8m, but underlying operating profit fell 7.5% to £24.5m and the underlying Operating Margin slipped to 10.3% from 11.9%. Statutory profit before tax was £18.8m, against £25.9m a year earlier, after a £6.7m Impairment of legacy countermeasures operations in Tennessee, partly offset by a £7.3m gain on derivatives. Underlying Diluted Earnings per Share fell 8% to 6.1p.

The divisional picture was split. Countermeasures & Energetics grew revenue 9.1% to £142.1m and lifted underlying operating profit 31.8% to £26.1m, an 18.4% margin. Sensors & Information grew revenue 2.8% to £95.2m but underlying operating profit fell 40.4% to £9.6m as UK order delays weighed on Roke, although divisional order intake rose 57.4% to £110m.

The closing order book reached £1,399m, up 8% year on year. Net debt climbed to £144.5m from £89.0m at the October 2025 year end, reflecting £44m of Capital Expenditure on energetics expansion. The Interim Dividend was raised 4% to 2.8p. Full-year expectations are unchanged, with operating profit around 70% weighted to the second half and cash conversion targeted at 80-85%.

For context, the year to 31 October 2025 produced revenue of £497.5m, underlying operating profit of £73.5m at a 14.8% margin, underlying diluted EPS of 19.4p and a total dividend of 8.0p.

What could drive the stock next?

The immediate catalyst is the post-close trading update that Chemring has typically issued in early November, followed by results in December; dates have not yet been published. Given the 70% second-half weighting, that update will show whether the group has delivered its unchanged FY26 guidance.

Capacity is the medium-term story. New energetics facilities in the United States, Scotland and Norway are respectively complete and ramping, in commissioning, and advancing. Management expects these projects to add around £100m of annual revenue and £30m of operating profit by 2028, and in December 2025 it set an ambition to roughly double revenue to £1bn by 2030.

Order coverage adds visibility: 91% of expected FY26 revenue was delivered or in the order book at the interim stage, with 81% of FY27 already covered. Publication of the UK Defence Investment Plan could unlock delayed Roke orders.

Risks investors should watch

Leverage is rising. Net debt has more than doubled since April 2025 and management expects it to remain elevated through FY27, while the estimated cost of the Norwegian expansion has already increased from £145m to about £180m. Further overruns, commissioning delays or a slower production ramp would push out the promised returns.

Execution risk has been visible: disruption at the Tennessee countermeasures site caused a slow start to FY26 and led to the impairment of legacy operations, and the heavy second-half weighting leaves little room for slippage.

UK exposure is a near-term headwind. Roke's profit fell sharply in the first half as the delayed Defence Investment Plan held back orders. Chemring also depends heavily on US government spending, so it is exposed to budget priorities, contract timing and dollar exchange rates. Finally, a CEO transition after eight years under one leader carries the risk of changed priorities.

Outlook

Chemring (LSE:CHG) enters the final quarter of its financial year with a record order book, strong US contract momentum and an investment case built on European and American rearmament. Against that sit weaker margins, rising debt, a UK order drought at Roke and a leadership handover. The November trading update, progress at the Norwegian and Scottish plants, and Tom Newman's early priorities will show whether the capacity expansion converts into the profit growth the board has targeted.